Paul Horstmeier - Mar 9, 2022 Form 4/A - Amendment Insider Report for Health Catalyst, Inc. (HCAT)

Role: Chief Operating Officer
Signature: /s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol: HCAT
Transactions as of: Mar 9, 2022
Transactions value $: -$450,652
Form type: 4/A - Amendment
Date filed: 4/8/2022, 05:36 PM
Date Of Original Report: Mar 11, 2022
Previous filing: Mar 3, 2022
Next filing: Apr 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCAT	Common Stock	Options Exercise	$8.25K	+521	+0.27%	$15.84	197K	Mar 9, 2022	Direct
transaction	HCAT	Common Stock	Options Exercise	$66K	+4.17K	+2.12%	$15.84	201K	Mar 9, 2022	Direct
transaction	HCAT	Common Stock	Sale	-$520K	-20.5K	-10.21%	$25.32	181K	Mar 9, 2022	Direct	F1, F2, F3
transaction	HCAT	Common Stock	Sale	-$5.23K	-201	-0.11%	$26.02	180K	Mar 9, 2022	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-4.17K	-9.53%	$0.00	39.6K	Mar 9, 2022	Common Stock	4.17K	$15.84	Direct	F5
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-521	-7.7%	$0.00	6.25K	Mar 9, 2022	Common Stock	521	$15.84	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person in accordance with Rule 10b5-1.
F2	Due to a technical and administrative error, the original Form 4, filed on March 11, 2022, incorrectly included the sale of 2,482 shares of Common Stock by the Reporting Person that did not occur and was duplicative of the sale of such 2,482 shares of Common Stock that were previously reported.
F3	Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from $25.00 to $25.96, inclusive.
F4	Represents the weighted average sale price of the shares sold ranging from $26.00 to $26.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (3) and (4).
F5	25% of the 186,467 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.
F6	25% of the 25,000 shares underlying the option vested in an annual installment and the remaining balance vested or will vest in equal monthly installments until the option vests in full on February 5, 2023.